UNSPSC 51262403: Amosulalol

This classification denotes an adrenergic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C69JI1BAU8. European Medicines Agency schedules Amosulalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Amosulalol generally arises in the molecular formula C18H24N2O5S.

UNSPSC 51262403 Amosulalol, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities posted under this code involve naloxone and safe drug deactivation systems (Seminole County, Florida) and a request for information on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), neither of which constitute procurement of amosulalol itself. State and local governments do not appear to be actively soliciting this specific pharmaceutical ingredient through recent competitive notices tagged to this code.

Seminole County's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through electronic bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Texas HHS's RFI HHS0017013, posted April 3, 2026, gathers vendor capabilities for a direct-to-manufacturer prescription program but does not specify procurement of amosulalol. The code's recent activity consists primarily of pharmaceutical-adjacent procurement by state health agencies and counties rather than direct amosulalol acquisition, suggesting the code may be misapplied to these opportunities or that amosulalol procurement through state and local channels remains inactive or coded differently in current solicitations.